Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSI-301 vs Aflibercept in Diabetic Macular Edema
CTR20212608Phase 3Terminated
- Sponsor
- Kodiak Sciences
- Start
- Oct 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tarcocimab tedromer in diabetic macular edema (DME), sponsored by Kodiak Sciences. Started Oct 2021; status: terminated.
02
Drugs
tarcocimab tedromer
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20212608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212608.